최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Annals of laboratory medicine, v.41 no.3, 2021년, pp.259 - 267
Lee, Min Young (Department of Laboratory Medicine, Kyung Hee University School of Medicine and Kyung Hee University Hospital, Gangdong, Seoul, Korea) , Park, Chan-Jeoung (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea) , Cho, Young-Uk (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea) , You, Eunkyoung (Department of Laboratory Medicine, Inje University College of Medicine, Busan Baik Hospital, Busan, Korea) , Jang, Seongsoo (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea) , Seo, Eul Ju (Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea) , Lee, Jung-Hee (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea) , Yoon, Dok Hyun (Department of Oncology, As) , Suh, Cheolwon
BackgroundPlasma cell myeloma (PCM) is caused by immune dysregulation. We evaluated the expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets in PCM patients according to disease course and cytogenetic abnormalities. This study aimed to find a target group suitable...
1 Patel SP Kurzrock R 2015 PD-L1 expression as a predictive biomarker in cancer immunotherapy Mol Cancer Ther 14 847 56 10.1158/1535-7163.MCT-14-0983 25695955
2 Lesokhin AM Ansell SM Armand P Scott EC Halwani A Gutierrez M 2016 Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study J Clin Oncol 34 2698 704 10.1200/JCO.2015.65.9789 27269947
3 Usmani SZ Schjesvold F Rocafiguera AO Karlin L Rifkin RM Yimer HA 2018 A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): Keynote-185 J Clin Oncol 36 8010 10.1200/JCO.2018.36.15_suppl.8010
4 Mateos MV Blacklock H Schjesvold F Rocafiguera AO Simpson D George A 2018 A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Keynote-183 J Clin Oncol 36 8021 10.1200/JCO.2018.36.15_suppl.8021
5 Palumbo A Avet-Loiseau H Oliva S Lokhorst HM Goldschmidt H Rosino L 2015 Revised international staging system for multiple myeloma: a report from International Myeloma Working Group J Clin Oncol 33 2863 9 10.1200/JCO.2015.61.2267 26240224
6 Mikhael JR Dingli D Roy V Reeder CB Buadi FK Hayman SR 2013 Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 Mayo Clin Proc 88 360 76 10.1016/j.mayocp.2013.01.019 23541011
7 Health Insurance Review & Assessment Service Healthcare big data hub http://opendata.hira.or.kr/op/opc/olap3thDsInfo.do Updated on Jan 2020
8 Kumar SK Rajkumar SV Dispenzieri A Lacy MQ Hayman SR Buadi FK 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 20 10.1182/blood-2007-10-116129 17975015
9 Lee HY Park CJ Ahn A Lee MY Cho YU Jang S Seo EJ Lee KH Lee JH Lee HY 2019 Two Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma Ann Lab Med 39 496 8 10.3343/alm.2019.39.5.496 31037870
10 Paiva B Azpilikueta A Puig N Ocio EM Sharma R Oyajobi BO 2015 PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma Leukemia 29 2110 3 10.1038/leu.2015.79 25778100
11 Stathopoulou C Gangaplara A Mallett G Flomerfelt FA Liniany LP Knight D 2018 PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells Immunity 49 247 63 e7 10.1016/j.immuni.2018.05.006 30054205
12 Amarnath S Costanzo CM Mariotti J Ullman JL Telford WG Kapoor V 2010 Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1 PLoS Biol 8 e1000302 10.1371/journal.pbio.1000302 20126379
13 Amarnath S Chen H Foley JE Costanzo CM Sennesh JD Solomon MA 2011 Host-based Th2 cell therapy for prolongation of cardiac allograft viability PLoS One 6 e18885 10.1371/journal.pone.0018885 21559526
14 Muthu Raja KR Rihova L Zahradova L Klincova M Penka M Hajek R 2012 Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma PLoS One 7 e47077 10.1371/journal.pone.0047077 23071717
15 Karnell FG Lin D Motley S Duhen T Lim N Campbell DJ 2017 Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation Clin Exp Immunol 189 268 78 10.1111/cei.12985 28498568
16 Arruda LCM de Azevedo JTC de Oliveira GLV Scortegagna GT Rodrigues ES Palma PVB 2016 Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation Clin Immunol 169 47 57 10.1016/j.clim.2016.06.005 27318116
17 Simonetta F Pradier A Bosshard C Masouridi-Levrat S Dantin C Koutsi A 2019 Dynamics of expression of programmed cell death protein-1 (PD-1) on T cells after allogeneic hematopoietic stem cell transplantation Front Immunol 10 1034 10.3389/fimmu.2019.01034 31156625
18 Merindol N Champagne MA Duval M Soudeyns H 2011 CD8(+) T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse Blood 118 4480 8 10.1182/blood-2011-04-349241 21813446
19 Pawlyn C Morgan GJ 2017 Evolutionary biology of high-risk multiple myeloma Nat Rev Cancer 17 543 56 10.1038/nrc.2017.63 28835722
20 Corrado C Raimondo S Chiesi A Ciccia F De Leo G Alessandro R 2013 Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications Int J Mol Sci 14 5338 66 10.3390/ijms14035338 23466882
21 Roccaro AM Sacco A Maiso P Azab AK Tai YT Reagan M 2013 BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression J Clin Invest 123 1542 55 10.1172/JCI66517 23454749
22 Raimondi L De Luca A Amodio N Manno M Raccosta S Taverna S 2015 Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation Oncotarget 6 13772 89 10.18632/oncotarget.3830 25944696
24 Neri P Ren L Azab AK Brentnall M Gratton K Klimowicz AC 2011 Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion Blood 117 6202 13 10.1182/blood-2010-06-292243 21474670
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.